Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...
Novartis
Novartis’s Lutathera Secures FDA Approval for Pediatric Gastroenteropancreatic NETs
The US Food and Drug Administration (FDA) has granted regulatory approval to Novartis (NYSE: NVS)...
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant...
Novartis’s Kesimpta Shows Sustained Efficacy in 6-Year Relapsing MS Study
Swiss pharmaceutical giant Novartis (NYSE: NVS) has this week unveiled six-year efficacy data for its...
Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...
EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion
AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...
Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...
Sandoz Agrees to $265 Million Settlement in U.S. Generic Drug Antitrust Case
Sandoz (SIX: SDZ), the Swiss-based pharmaceutical company, announced this week that its U.S. subsidiaries have...
Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration
Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...
FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up
The U.S. Food and Drug Administration (FDA) has granted approval to Takeda Pharmaceutical Company (TYO:...
Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion
Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...
Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments
Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...
Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...
Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...